Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
Understanding Semaglutide and Its Benefits Semaglutide is a GLP-1 receptor agonist approved by the FDA for managing chronic weight issues in adults with obesity or those overweight with related health conditions
Table of Contents What Is Retatrutide and Its Current Development Status in the UK Risks of Sourcing Unregulated Peptides Online MHRA Guidance on Unlicensed Weight Loss Treatments Approved Alternatives Available Through NHS and Private Clinics How to Speak to a UK Doctor About Emerging Weight Loss Options Scientific References Frequently Asked Questions What Is Retatrutide and Its Current Development Status in the UK Retatrutide is an investigational triple incretin receptor agonist (GLP-1, GIP, and glucagon) developed by Eli Lilly that remains in Phase 3 trials and holds no MHRA marketing authorisation as of mid-2025
Soni R, Durgapal SD, Soman SS, Georrge JJ
If you are deciding between semaglutide and tirzepatide, the right answer depends on your medical history, goals, and tolerance
